TransMedics Group, Inc. (TMDX Quick QuoteTMDX - Free Report) is well-poised for growth in the coming quarters, courtesy of its strength in Organ Care System (“OCS”) technology. The optimism, led by solid fourth-quarter 2025 results, is expected to contribute further. However, concerns due to gross margin pressure persist.

This Zacks Rank #3 (Hold) company has lost 4.4% in the past six months compared with 3.6% decline in the industry. The S&P 500 has witnessed 0.6% growth in the said time frame.

The renowned organ transplant therapy provider has a market capitalization of $3.84 billion. TransMedics’ earnings yield of 2.17% compares favorably with the industry’s negative 1.68%. The company’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 87.61%.

Image Source: Zacks Investment Research

Factors Favoring TMDX’s Growth

Robust Pipeline Supporting Growth: TransMedics is seeing solid progress across its clinical pipeline, with the ENHANCE Heart and DENOVO Lung trials, both FDA-cleared, moving into early activation and enrolment. While ENHANCE has faced some competitive friction in Part B, management remains confident in execution and expects these trials to generate strong clinical evidence to support broader adoption of OCS Heart and Lung. Any near-term softness in volumes is viewed as temporary, with momentum likely to build as these programs ramp through 2026.

Looking ahead, the OCS Kidney program represents a major long-term opportunity, targeting the largest transplant segment with high unmet need. Development is on track for FDA trials by early 2027, with the system designed as a next-generation warm perfusion solution spanning the full donor-to-recipient process. Alongside this, TransMedics is advancing the OCS Gen 3 platform and scaling the NOP Connect digital ecosystem, which is already improving coordination, efficiency and transparency, strengthening its integrated, defensible growth strategy.

Strength in OCS Technology Driving Adoption: TransMedics’ OCS revolutionizes organ transplantation by replacing passive cold storage with a dynamic, physiologic approach that perfuses donor organs with warm, oxygenated, nutrient-rich blood. This innovation minimizes ischemic injury, allows real-time organ assessment and significantly increases the viability of organs, especially hearts and lungs, donated after circulatory death, that would otherwise go unused.

As the only FDA-approved, portable platform offering warm perfusion for heart, lung and liver transplants, the OCS standardizes care, reduces post-transplant complications and sets a new clinical benchmark in organ preservation. This positions TransMedics as a leader in the multi-billion-dollar transplant market with limited competition.

Solid Q4 Results: TransMedics exited fourth-quarter 2025 with better-than-expected results. The solid top and bottom-line performances and the uptick in Transplant Logistics services revenues were encouraging. Strength in both revenue sources was also impressive. The expansion of the operating margin bodes well.

In 2026, the company is focused on accelerating growth by expanding clinical indications, geographic reach and next-generation technology across its OCS platform. Upcoming catalysts include the ENHANCE Heart and DENOVO Lung programs, both FDA-cleared and progressing through enrolment, with updates expected at ISHLT.

Factor That Can Offset the Gains for TMDX

Gross Margin Under Pressure: TransMedics reported a gross margin of approximately 58% in the fourth quarter of 2025, reflecting a decline of about 110 basis points year over year and roughly 70 basis points sequentially. While the company continued to deliver strong top-line growth, the margin compression highlights ongoing cost pressures tied to its scaling model.

Management attributed the year-over-year decline primarily to higher clinical service costs associated with the expansion of the NOP program, along with logistics-related discounts and elevated freight expenses. On a sequential basis, margins were further impacted by inventory-related charges and higher expedited shipping costs, particularly as the company replenished inventory toward year-end.

Estimate Trend

TransMedics is witnessing a negative earnings estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings moved 28 cents south to $2.43 per share.

The Zacks Consensus Estimate for the company’s first-quarter 2026 revenues is pegged at $175.6 million, indicating a 22.3% improvement from the year-ago quarter’s reported number.

Key Picks

Some better-ranked stocks in the broader medical space that have announced quarterly results are Intuitive Surgical (ISRG Quick QuoteISRG - Free Report) , Phibro Animal Health (PAHC Quick QuotePAHC - Free Report) and Cardinal Health (CAH Quick QuoteCAH - Free Report) .

Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.

Phibro Animal Health reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. It currently flaunts a Zacks Rank #1.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.5% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.

Cardinal Health reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%. It currently carries a Zacks Rank #2 (Buy).

CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.